Still smarting from the frustration of scaling up their limited pandemic response capabilities to produce COVID-19 vaccines and therapeutics, officials with the US government’s Biomedical Advanced Research and Development Authority, or BARDA, shared insights on a 20 January call regarding the industry input sought to help them decide how to prepare for future pandemics.
Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response
BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.
